At a Glance
Gland Pharma kicked off Q1 FY26 with ₹1,505 Cr revenue (+7% YoY) and ₹215 Cr PAT (+50% YoY), while EBITDA margins stayed a healthy 24%. The company’s European arm Cenexi finally hit EBITDA breakeven, proving it’s not just a cash sinkhole. With new molecule launches and strong US market traction, Gland has injected investor confidence straight into the bloodstream.
Introduction
Imagine a pharma company that quietly manufactures complex injectables and then quietly mints money. That’s Gland. Backed by Shanghai Fosun, it’s India’s injectable wizard with a growing global footprint. While other pharma giants battle USFDA love letters, Gland is focused on scaling products across markets. The catch? Growth has been sluggish in recent years, and the stock’s P/E at 42x still assumes it’s on a growth hormone cycle.
Business Model (WTF Do They Even Do?)
- Core: Development, manufacturing, and supply of sterile injectables.
- Products: 89+ SKUs including oncology, ophthalmic, and specialty injectables.
- Revenue Model: B2B exports to 60+ countries, with US & EU as key markets.
- New Edge: Acquisitions like Cenexi to expand EU footprint.
Roast: They make the shots that save lives while giving investors an adrenaline shot with Q1 numbers.
Financials Overview
Q1 FY26 Numbers
- Revenue: ₹1,505 Cr (+7% YoY)
- EBITDA: ₹368 Cr (24% margin)
- PAT: ₹215 Cr (+50% YoY)
- EPS: ₹13.1
FY25 Snapshot
- Revenue: ₹5,616 Cr
- PAT: ₹699 Cr
- ROE: 7.8%
- ROCE: 11.9%
Commentary: Revenue growth is modest, but the sharp rise in profit signals operational efficiency improvements.
Valuation
1. P/E Method
- EPS FY25: ₹42.4 × P/E 25–30 → ₹1,060 – ₹1,270
2. EV/EBITDA
